Why ImmunityBio Stock Is Skyrocketing Again Today

Key Points ImmunityBio announced this morning that it had reached a major enrollment threshold for one of its clinical trials. It also highlighted initial success in treating patients with Non-Hodgkin lymphoma with one of its next-gen therapies. These developments follow four other significant business updates from earlier this week that have helped the stock double in five days. 10 stocks we like better than ImmunityBio › Shares of cancer and infectious disease therapy developer ImmunityBio, In ...